{
  "@context": "aku-v2",
  "@type": "definition",
  "@id": "vascular:thrombophilia:prothrombin-mutation:definition",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-05T18:01:00.000Z",
    "contributors": ["copilot"],
    "status": "validated",
    "confidence": 0.93
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/thrombophilia",
    "type": "definition",
    "difficulty": "intermediate",
    "importance": "foundational",
    "board_yield": "HIGH"
  },
  "content": {
    "term": "Prothrombin Gene Mutation",
    "synonyms": ["Prothrombin G20210A", "Factor II Mutation", "Prothrombin Thrombophilia"],
    "definition": "An inherited thrombophilia caused by a point mutation (G20210A) in the 3' untranslated region of the prothrombin (Factor II) gene, resulting in elevated plasma prothrombin levels and increased risk of venous thromboembolism. It is the second most common inherited thrombophilia after Factor V Leiden.",
    "genetics": {
      "mutation": "G20210A in 3' UTR of prothrombin gene",
      "inheritance": "Autosomal dominant",
      "prevalence": [
        "2-3% of Caucasians (heterozygotes)",
        "Rare in Asian and African populations",
        "Homozygotes very rare"
      ]
    },
    "pathophysiology": {
      "mechanism": [
        "Mutation affects mRNA stability/processing",
        "Increased prothrombin mRNA levels",
        "30% higher plasma prothrombin (Factor II) levels",
        "More thrombin generation potential"
      ]
    },
    "clinical_significance": {
      "vte_risk": {
        "heterozygotes": "2-5 fold increased risk",
        "homozygotes": "Rare, higher risk"
      },
      "combined_with_other_thrombophilias": [
        "Additive or synergistic risk",
        "FVL + Prothrombin mutation = higher risk"
      ],
      "associations": [
        "Deep vein thrombosis",
        "Pulmonary embolism",
        "Cerebral vein thrombosis",
        "Possibly stroke in young patients"
      ]
    },
    "diagnosis": {
      "genetic_testing": [
        "PCR for G20210A mutation",
        "No functional assay available",
        "Must be confirmed genetically"
      ],
      "prothrombin_levels": [
        "Elevated in carriers",
        "Not diagnostic alone (overlap with normal)"
      ],
      "when_to_test": [
        "Same indications as Factor V Leiden testing",
        "Often tested together"
      ]
    },
    "management": {
      "same_as_fvl": "Management parallels Factor V Leiden",
      "acute_vte": "Standard anticoagulation",
      "duration": "Based on provoked vs unprovoked, recurrence risk",
      "prevention": [
        "Avoid additional risk factors when possible",
        "Prophylaxis in high-risk situations"
      ]
    }
  },
  "codes": {
    "snomed_ct": "441682002",
    "icd_10": "D68.52"
  },
  "relationships": {
    "broader": ["vascular:thrombophilia:inherited"],
    "related": ["vascular:thrombophilia:factor-v-leiden", "vascular:dvt:risk-factors"],
    "narrower": []
  },
  "pedagogical": {
    "learning_objectives": [
      "Know that Prothrombin G20210A is second most common inherited thrombophilia",
      "Understand the mechanism (increased prothrombin levels)",
      "Know VTE risk is lower than Factor V Leiden"
    ],
    "clinical_pearls": [
      "Second most common inherited thrombophilia after FVL",
      "2-3% Caucasian prevalence",
      "Heterozygotes: 2-5x VTE risk (lower than FVL)",
      "Increases prothrombin levels by ~30%",
      "No functional assay - must test genetically",
      "Often co-inherited with FVL - additive risk"
    ]
  }
}
